These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 19860731)

  • 1. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
    Brandt GE; Blagg BS
    Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
    Prodromou C
    Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action.
    Matts RL; Manjarrez JR
    Curr Top Med Chem; 2009; 9(15):1462-78. PubMed ID: 19860729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
    Gao J; Zhou C; Zhong Y; Shi L; Luo X; Su H; Li M; Xu Y; Zhang N; Zhou H
    Biochem Pharmacol; 2023 Jan; 207():115376. PubMed ID: 36513142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
    Koay YC; Wahyudi H; McAlpine SR
    Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
    Bickel D; Gohlke H
    Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90: the cancer chaperone.
    Neckers L
    J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
    Gavenonis J; Jonas NE; Kritzer JA
    Bioorg Med Chem; 2014 Aug; 22(15):3989-93. PubMed ID: 24984936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines.
    Lee T; Seo YH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6427-31. PubMed ID: 24125885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative approaches to Hsp90 modulation for the treatment of cancer.
    Hall JA; Forsberg LK; Blagg BS
    Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibition with resorcyclic acid lactones (RALs).
    Winssinger N; Fontaine JG; Barluenga S
    Curr Top Med Chem; 2009; 9(15):1419-35. PubMed ID: 19860733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of the Hsp90α Isoform.
    Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
    Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.